GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
To Assess the Cutaneous Irritation and Sensitization Potential of a Cosmetic Facial Product Using a Human Repeat Insult Patch Test (HRIPT) in Healthy Participants
Not Applicable
Completed
- Conditions
- Skin Care
- Interventions
- Other: Facial micellar cleanser
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 272
- Registration Number
- NCT03175562
- Locations
- 🇧🇷
GSK Investigational Site, Valinhos, Brazil
To Investigate the Cutaneous and Ocular Local Tolerance of Two Cosmetic Facial Cleanser in Healthy Females With Sensitive Skin
Not Applicable
Completed
- Conditions
- Skin Care
- Interventions
- Other: Micellar foaming cleanserOther: Micellar cleanser
- First Posted Date
- 2017-06-01
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 122
- Registration Number
- NCT03172364
- Locations
- 🇧🇷
GSK Investigational Site, Campinas, São Paulo, Brazil
Accurate Recognition of Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Completed
- Conditions
- Airway Obstruction
- Interventions
- Other: Draft item setOther: Focus group interviewOther: Candidate item set
- First Posted Date
- 2017-05-31
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 199
- Registration Number
- NCT03170999
- Locations
- 🇨🇳
GSK Investigational Site, Shenyang, China
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
Phase 1
Terminated
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT03168438
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Terminated
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: PlaceboDevice: Metered dose inhaler (MDI) sensor deviceDrug: Rescue medication
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 54
- Registration Number
- NCT03170232
- Locations
- 🇺🇸
GSK Investigational Site, Houston, Texas, United States
Patient Characteristics and Treatment Modalities in COPD Patients in China
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2017-05-22
- Last Posted Date
- 2019-06-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 848
- Registration Number
- NCT03161587
- Locations
- 🇨🇳
GSK Investigational Site, Zhengzhou, China
Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults
Phase 2
Completed
- Conditions
- Malaria
- Interventions
- Biological: RTS,S/AS01EBiological: RTS,S/AS01BProcedure: Sporozoite-infected mosquitoes challenge.
- First Posted Date
- 2017-05-22
- Last Posted Date
- 2020-10-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 154
- Registration Number
- NCT03162614
- Locations
- 🇺🇸
GSK Investigational Site, Silver Spring, Maryland, United States
Study to Investigate the Stain Control of Two Stannous Fluoride Dentifrices
Not Applicable
Completed
- Conditions
- Extrinsic Dental StainOral Hygiene
- Interventions
- Other: Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), abrasive silica (3.5%)Other: Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), 2.0% abrasive silicaOther: Sodium Monofluorophosphate (1000 ppm fluoride ), RDA~80Other: Stannous fluoride (SnF2, 0.454%), RDA~120
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 220
- Registration Number
- NCT03160703
- Locations
- 🇨🇦
GSK Investigational Site, Mississauga, Ontario, Canada
A Study to Measure the Sun Protection Factor (SPF) and Ultraviolet-A Protection Factor (UVAPF) of Four Developmental Sunscreen Formulations
Not Applicable
Completed
- Conditions
- Sunscreening Agents
- Interventions
- Other: GlycerinOther: NGBUV000D, (Expected SPF 30)Other: Sunscreen formulation S2Other: P3 Standard, (Expected SPF 16)Other: NGBUV000A, (Expected SPF 30)Other: NGBUV000C, (Expected SPF 30)Other: NGBUV000B, (Expected SPF 30)
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2019-07-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 8
- Registration Number
- NCT03157583
- Locations
- 🇩🇪
GSK Investigational Site, Schenefeld, Schleswig-Holstein, Germany
To Investigate the Impact of a Nutritional Supplement on Bone Turnover Markers in Indian Healthy Premenopausal Women (25- 45 Years) After 6 Months of Intervention
Not Applicable
Completed
- Conditions
- Growth and Development
- Interventions
- Dietary Supplement: Fortified Beverage PowderDietary Supplement: Non fortified beverage Powder
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 114
- Registration Number
- NCT03155269
- Locations
- 🇮🇳
GSK Investigational Site, Pune, India
© Copyright 2025. All Rights Reserved by MedPath